ESMO 2014

Updated CONCUR Trial Data: Regorafenib Monotherapy in Asian Patients with Metastatic Colorectal Cancer

Conference Correspondent - ESMO 2014 - Gastrointestinal and Head & Neck Cancer

The oral multikinase inhibitor regorafenib has demonstrated significant improvements in overall survival (OS) in previously treated patients with metastatic colorectal cancer (mCRC) whose disease has failed to respond to standard therapies. The randomized, placebo-controlled, phase 3 CONCUR trial evaluated the [ Read More ]

MACRO-2 Trial: Maintenance Therapy with Single-Agent Cetuximab plus Chemotherapy after Cetuximab-Based Induction for Patients with Metastatic Colorectal Cancer

Conference Correspondent - ESMO 2014 - Gastrointestinal and Head & Neck Cancer

The treatment options in patients with metastatic colorectal cancer (mCRC) include chemotherapy and targeted agents. Single-agent bevacizumab has been evaluated as maintenance therapy after induction therapy with bevacizumab plus chemotherapy; however, the role of cetuximab in this setting has not [ Read More ]

Subanalysis of TROPIC Trial: Cabazitaxel plus Prednisone versus Mitoxantrone after Docetaxel in Patients with Different Prognostic Risk Factors

Conference Correspondent - ESMO 2014 - Prostate Cancer

Previous results of the TROPIC trial showed that patients with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with cabazitaxel plus prednisone (CP) had improved overall survival (OS) compared with patients who received mitoxantrone plus prednisone (MP; Bahl A, et [ Read More ]